Galderma Group AG (XSWX:GALD) Buildings And Improvements: CHF0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:GALD Galderma Group AG XSWX:GALD
15 GF Score
Price CHF170.95
! 3 Warning Signs
View Full Analysis

What is Galderma Group AG Buildings And Improvements?

Galderma Group AG XSWX:GALD -0.03% 15 Buildings And Improvements is CHF0 Mil as of Jun. 2026. GuruFocus rates XSWX:GALD with a GF Score™ of 15/100. The stock has 3 warning signs investors should review.

Galderma Group AG's quarterly buildings and improvements increased from Jun. 2025 (CHF0 Mil) to Dec. 2025 (CHF81 Mil) but then declined from Dec. 2025 (CHF81 Mil) to Jun. 2026 (CHF0 Mil).

Galderma Group AG's annual buildings and improvements declined from Dec. 2023 (CHF74 Mil) to Dec. 2024 (CHF66 Mil) but then increased from Dec. 2024 (CHF66 Mil) to Dec. 2025 (CHF81 Mil).

Galderma Group AG Buildings And Improvements Historical Data

* Premium members only.

The historical data trend for Galderma Group AG's Buildings And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Galderma Group AG Buildings And Improvements Chart

Galderma Group AG Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Buildings And Improvements
0.00 0.00 74.37 65.98 81.28

Galderma Group AG Semi-Annual Data
Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Buildings And Improvements Get a 7-Day Free Trial 69.72 65.98 0.00 81.28 0.00
XSWX:GALD
15GF Score
Galderma Group AG XSWX:GALD
Buildings And Improvements is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Galderma Group AG Buildings And Improvements Calculation

Buildings are typically valued at the time of acquisition or construction.  Broker and architect fees, permits, etc. can be covered within this category.  Building components, such as a roof, are normally recorded separately in an asset register since the value and useful lives of these components equal much less than the building itself.

Building improvements that extend the useful life of a building will fall into the category of “building improvements” and should be capitalized.  Improvements are commonly recorded at acquisition cost.  Building improvement examples include roofing, remodeling, replacements, etc.

What does a Buildings And Improvements of CHF0 Mil mean?
Galderma Group AG (XSWX:GALD) has a Buildings And Improvements of CHF0 Mil as of Jun. 2026. Buildings and improvements is the total value of a company's buildings and improvements to them. View historical data on Galderma Group AG and its competitors.
Is Galderma Group AG's Buildings And Improvements too high?
Galderma Group AG's current Buildings And Improvements is CHF0 Mil. Overall, Galderma Group AG has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Galderma Group AG's Buildings And Improvements compare to ZTS and UTHR?
Galderma Group AG's Buildings And Improvements of CHF0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buildings And Improvements for a Drug Manufacturers company?
A good Buildings And Improvements depends on the Drug Manufacturers industry context. However, Buildings And Improvements should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buildings And Improvements mean?
A high Buildings And Improvements can signal that a stock is expensive relative to its fundamentals. Buildings and improvements is the total value of a company's buildings and improvements to them. View historical data on Galderma Group AG and its competitors. Galderma Group AG's current Buildings And Improvements is CHF0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Galderma Group AG stock overvalued right now?
Galderma Group AG (XSWX:GALD) has a current Buildings And Improvements of CHF0 Mil. The current Buildings And Improvements is CHF0 Mil. Galderma Group AG's overall GF Score™ is 15/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buildings And Improvements calculated?
Buildings And Improvements is calculated from a company's financial statements. For Galderma Group AG (XSWX:GALD), the current Buildings And Improvements is CHF0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Galderma Group AG Business Description

Address Zahlerweg 10, Zug, CHE, 6300
Galderma was formed in 1981 as a joint venture between Nestle and L'Oreal. It subsequently became a subsidiary of Nestle, called Nestle Skin Health, before being carved out and launched as a stand-alone company in 2019, acquired by a consortium led by Sweden-based EQT fund. The company went public in March 2024 and is listed on the SIX Swiss exchange. Galderma's science-based portfolio spans multiple dermatology categories, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. It derives around 40% of net sales from the US and employs more than 7,500 people.
15GF Score

Get the complete analysis for XSWX:GALD

Buildings And Improvements is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF170.95
Price